Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy

被引：0
|
作者：
Juliane Klehmet
Björn Tackenberg
Judith Haas
Bernd C. Kieseier
机构：
[1] Charité - Universitätsmedizin Berlin,Klinik Fur Neurologie
[2] Neurocure Clinical Research Center Berlin,undefined
[3] Jüdisches Krankenhaus Berlin,undefined
[4] Klinik Und Poliklinik Für Neurologie,undefined
[5] Heinrich-Heine Universität,undefined
来源：
BMC Neurology | / 23卷
关键词：
CIDP; IVIG; Real-world evidence; Patient-reported outcome measures; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 36 条
  • [1] Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
    Klehmet, Juliane
    Tackenberg, Bjorn
    Haas, Judith
    Kieseier, Bernd C. C.
    BMC NEUROLOGY, 2023, 23 (01)
  • [2] LONG-TERM OUTCOME IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY PATIENTS TREATED WITH INTRAVENOUS IMMUNOGLOBULIN: A RETROSPECTIVE STUDY
    Querol, Luis
    Rojas-Garcia, Ricard
    Casasnovas, Carlos
    Jose Sedano, Maria
    Luis Munoz-Blanco, Jose
    Antonia Alberti, Maria
    Paradas, Carmen
    Sevilla, Teresa
    Pardo, Julio
    Luis Capablo, Jose
    Sivera, Rafael
    Guerrero, Antonio
    Gutierrez-Rivas, Eduardo
    Illa, Isabel
    MUSCLE & NERVE, 2013, 48 (06) : 870 - 876
  • [3] LONG-TERM IMMUNOGLOBULIN THERAPY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
    Rajabally, Yusuf A.
    MUSCLE & NERVE, 2015, 51 (05) : 657 - 661
  • [4] Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
    Terhoeven, Pauline
    Seybold, Julia
    Utz, Kathrin S.
    Nickel, Florian T.
    Lee, De-Hyung
    Linker, Ralf A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 419
  • [5] Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up
    Jann, S.
    Bramerio, M. A.
    Facchetti, D.
    Sterzi, R.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (01) : 70 - 73
  • [6] Efficiency of long-term treatment with intravenous immunoglobulins correlates with reduced autoreactive T cell responses in chronic inflammatory demyelinating polyneuropathy patients
    Klehmet, J.
    Meisel, C.
    Meisel, A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 178 : 149 - 150
  • [7] CHANGES IN SPATIOTEMPORAL GAIT PARAMETERS FOLLOWING INTRAVENOUS IMMUNOGLOBULIN TREATMENT FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
    Vo, Mary L.
    Chin, Russell L.
    Miranda, Caroline
    Latov, Norman
    MUSCLE & NERVE, 2017, 56 (04) : 732 - 736
  • [8] Improvement of Axonal Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy After Intravenous Immunoglobulin Therapy
    Hughes, Richard A. C.
    Mills, Kerry
    ARCHIVES OF NEUROLOGY, 2011, 68 (07) : 844 - 846
  • [9] Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin
    Vu, Tuan
    Anthony, Natalie
    Alsina, Raul
    Harvey, Brittany
    Schleutker, Allison
    Farias, Jerrica
    Dang, Samuel
    Suresh, Niraja
    Gooch, Clifton
    MUSCLE & NERVE, 2021, 64 (03) : 351 - 357
  • [10] Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy
    Hansen, Peter N. N.
    Mohammed, Abdullahi A. A.
    Markvardsen, Lars K. K.
    Andersen, Henning
    Tankisi, Hatice
    Sindrup, Soren H.
    Kroigard, Thomas
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2023, 28 (03) : 425 - 435
1234